Ariel Birnbaum, MD
Hematology & Oncology · Providence, RINPI 1942212790
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $325 of the $495 with a category attached, or 65.6%. Sanofi accounts for 65.6% of it on its own, with 2 other manufacturers making up the rest.
Across 5 payments — averaging $99.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$325
- E.r. Squibb & Sons, L.L.C.$125
- Bausch & Lomb Americas Inc.$46
Across 11 payments — averaging $26,751 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$256K
- Eli Lilly$16K
- Macrogenics, Inc.$16K
- Pfizer$6K
- Regeneron$439
What the payments were for
- Speaking & faculty fees$32566%
- Food & beverage$17034%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 2 | $325 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Bausch & Lomb Americas Inc. | 2 | $46 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPRELSA$325
How this compares
$495 in reported general payments places this provider in the 55th percentile of 68 hematology & oncology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 24 | $391,757 |
| LeukineSargramostim | 13 | $53,018 |
| Buprenorphine | 16 | $2,953 |
| Oxycodone Hcl | 58 | $1,183 |
| Famotidine | 13 | $938 |
| Prochlorperazine Maleate | 63 | $818 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $663 |
| Gabapentin | 40 | $568 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $412 |
| Mirtazapine | 27 | $390 |
| Ibuprofen | 35 | $390 |
| Ondansetron Hcl | 48 | $357 |
| Lidocaine Hcl ViscousLidocaine Hcl | 16 | $335 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 14 | $272 |
| Levothyroxine Sodium | 38 | $236 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Providence
- William SikovProvidence$156K
- Ritesh RathoreProvidence$148K
- Anthony MegaProvidence$65K
- Adam OlszewskiProvidence$63K
- Hina KhanProvidence$34K
- Peter BarthProvidence$29K
- Thomas OllilaProvidence$19K
- John ReaganProvidence$18K
- Jennifer GassProvidence$16K
- Matthew HadfieldProvidence$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.